SUPN News and Press, Supernus Pharmaceuticals Inc. From 08/04/21

Supernus Pharmaceuticals (NASDAQ:SUPN): Q2 GAAP EPS of $0.43 beats by $0.23. Revenue of $141.3M (+11.5% Y/Y) beats by $5.8M. As of June 30, 2021, the Company had $855.3 million in cash, cash equivalents, current and long-term marketable securities, compared to $772.9 million as of December 31...

Second quarter 2021 total revenues of $141.3 million, a 12% increase compared to 2020 Qelbree™ launched in the U.S. for pediatric ADHD at the end of May 2021 Qelbree sNDA for adult ADHD submitted to the FDA SPN-830 (apomorphine infusion pump) NDA resubmission anticipate...

Supernus Pharmaceuticals (SUPN -5.0%) is trading lower in morning hours after the company announced the resignation of its chief financial officer, James P. Kelly, effective August 13. On July 27, the company has appointed Timothy C. Dec as its new senior vice-president and CFO with effe...

ROCKVILLE, Md., July 22, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fina...

Supernus Pharmaceuticals (SUPN) has entered into an exclusive agreement with Bachem Americas, under which the latter will be responsible for the supply of viloxazine hydrochloride, the active pharmaceutical ingredient (“API”) of Qelbree extended-release capsules.In April, the FD...

Biotechs are ready to march forcefully higher after a lengthy consolidation. Approval of Biogen's Alzheimer's treatment creates a bonanza for neurodegenerative-focused companies and the overall biotech sector. The lower bar set for approval poses risk for Biogen in the out years. ...

Healthcare faces an important decision as the Supreme Court decides on the Affordable Care Act. Biotechs face an important FDA decision on approval of an Alzheimer's treatment. Oncology companies get ready to present new data at the largest US oncology conference with potential fo...

ROCKVILLE, Md., May 25, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that Jack Khattar, President and CEO of ...

ROCKVILLE, Md., May 24, 2021 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that its recent U.S. Food and Drug Admin...

We did a comparison of 3 small-cap biotech stocks (SUPN, ENTA & EGRX) which were ranked highly in our quantitative model. SUPN demonstrated outperformance in growth and profitability metrics. Both SUPN and EGRX are led by Founder-CEO. Overall, we believe SUPN could be a lo...